

This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older.
Study details include:





Check your eligibility to see if you may qualify for this clinical study
Thank you for your interest in learning more about this clinical study.
Please take a few minutes to complete this eligibility questionnaire. The questions will ask about your symptoms, medical history, and other basic health information that may be relevant to the study.
Please answer each question as accurately and completely as possible. Completing this questionnaire does not guarantee eligibility or participation in the clinical study. Final eligibility will be determined by the study team based on the complete study requirements and any additional assessments that may be needed.
If you appear to be a potential match, you will be provided with information about the next steps and how you can learn more about participating in the study.
Estimated time: A few minutes to complete.
The prescreener preview is complete. You may now close the preview.
